MYOCD
Basic information
Region (hg38): 17:12665890-12768949
Links
Phenotypes
GenCC
Source:
- megabladder, congenital (Limited), mode of inheritance: AD
- megabladder, congenital (Limited), mode of inheritance: Unknown
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Megabladder, congenital | AD | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Genitourinary; Renal | 31513549 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the MYOCD gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 8 | |||||
missense | 47 | 56 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | ||||
non coding | 24 | 24 | ||||
Total | 0 | 0 | 47 | 3 | 38 |
Variants in MYOCD
This is a list of pathogenic ClinVar variants found in the MYOCD region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
17-12666125-G-A | Benign (Jun 20, 2021) | |||
17-12666195-C-T | not specified | Uncertain significance (Apr 19, 2024) | ||
17-12666245-T-C | Megabladder, congenital | Likely pathogenic (-) | ||
17-12704954-T-C | Benign (Jun 20, 2021) | |||
17-12705154-A-G | not specified | Uncertain significance (Mar 06, 2023) | ||
17-12705181-G-C | not specified | Uncertain significance (Jul 09, 2021) | ||
17-12715310-C-CCT | Benign (Nov 12, 2018) | |||
17-12715363-G-C | Benign (Jun 20, 2021) | |||
17-12715534-C-A | not specified | Uncertain significance (Oct 12, 2024) | ||
17-12717394-G-A | Benign (May 08, 2017) | |||
17-12717398-TG-T | Megabladder, congenital | Likely pathogenic (Oct 08, 2024) | ||
17-12717444-A-G | Benign (Nov 12, 2018) | |||
17-12717580-G-A | Benign (Nov 12, 2018) | |||
17-12722609-G-A | Benign (Jun 20, 2021) | |||
17-12722936-C-T | Prune belly syndrome • Megabladder, congenital | Pathogenic (Dec 23, 2019) | ||
17-12722951-G-A | not specified | Uncertain significance (May 31, 2023) | ||
17-12722952-A-G | not specified | Uncertain significance (Oct 12, 2022) | ||
17-12735977-T-C | Benign (Nov 12, 2018) | |||
17-12736168-G-A | Benign (Jun 09, 2021) | |||
17-12736251-G-A | Megabladder, congenital • not specified | Conflicting classifications of pathogenicity (Sep 01, 2024) | ||
17-12736272-C-T | not specified | Uncertain significance (Sep 08, 2024) | ||
17-12736282-G-A | Likely benign (Oct 01, 2024) | |||
17-12736288-C-T | Uncertain significance (-) | |||
17-12736311-C-T | not specified | Likely benign (Oct 19, 2024) | ||
17-12738949-TTA-T | Benign (Jun 20, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
MYOCD | protein_coding | protein_coding | ENST00000425538 | 14 | 103060 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.334 | 0.666 | 125728 | 0 | 20 | 125748 | 0.0000795 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.336 | 517 | 539 | 0.959 | 0.0000281 | 6463 |
Missense in Polyphen | 197 | 214.38 | 0.91894 | 2654 | ||
Synonymous | -1.28 | 251 | 227 | 1.11 | 0.0000136 | 1975 |
Loss of Function | 4.73 | 10 | 43.8 | 0.228 | 0.00000245 | 468 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000905 | 0.0000905 |
Ashkenazi Jewish | 0.000496 | 0.000496 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000885 | 0.0000879 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.0000431 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Smooth muscle cells (SM) and cardiac muscle cells- specific transcriptional factor which uses the canonical single or multiple CArG boxes DNA sequence. Acts as a cofactor of serum response factor (SRF) with the potential to modulate SRF-target genes. Plays a crucial role in cardiogenesis and differentiation of the smooth muscle cell lineage (myogenesis) (By similarity). {ECO:0000250, ECO:0000269|PubMed:12640126}.;
- Pathway
- SRF and miRs in Smooth Muscle Differentiation and Proliferation;PDGFR-beta signaling pathway
(Consensus)
Recessive Scores
- pRec
- 0.216
Intolerance Scores
- loftool
- 0.0234
- rvis_EVS
- -0.68
- rvis_percentile_EVS
- 15.39
Haploinsufficiency Scores
- pHI
- 0.453
- hipred
- Y
- hipred_score
- 0.594
- ghis
- 0.527
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.653
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Myocd
- Phenotype
- muscle phenotype; homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype;
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;regulation of cell growth by extracellular stimulus;vasculogenesis;response to hypoxia;cardiac ventricle development;positive regulation of transcription from RNA polymerase II promoter involved in myocardial precursor cell differentiation;positive regulation of cell population proliferation;negative regulation of cell population proliferation;negative regulation of cardiac muscle cell apoptotic process;negative regulation of myotube differentiation;positive regulation of transforming growth factor beta receptor signaling pathway;cardiocyte differentiation;regulation of histone acetylation;vascular smooth muscle cell differentiation;positive regulation of DNA binding;cellular component maintenance;regulation of myoblast differentiation;negative regulation of cyclin-dependent protein serine/threonine kinase activity;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;positive regulation of smooth muscle contraction;lung alveolus development;digestive tract development;positive regulation of DNA-binding transcription factor activity;smooth muscle cell differentiation;regulation of smooth muscle cell differentiation;positive regulation of smooth muscle cell differentiation;cardiac muscle cell differentiation;ventricular cardiac muscle cell differentiation;uterus development;urinary bladder development;ductus arteriosus closure;negative regulation of amyloid-beta clearance;regulation of phenotypic switching;negative regulation of vascular smooth muscle cell proliferation;negative regulation of vascular associated smooth muscle cell migration;negative regulation of platelet-derived growth factor receptor-beta signaling pathway;positive regulation of transcription from RNA polymerase II promoter involved in smooth muscle cell differentiation;positive regulation of cardiac vascular smooth muscle cell differentiation;positive regulation of cardiac muscle cell differentiation;negative regulation of skeletal muscle cell differentiation
- Cellular component
- nuclear chromatin;nucleus
- Molecular function
- RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription activator activity, RNA polymerase II-specific;transcription coactivator activity;protein binding;transcription factor binding;histone acetyltransferase binding;histone deacetylase binding;RNA polymerase II-specific DNA-binding transcription factor binding;R-SMAD binding